Gufic Biosciences Limited (NSE:GUFICBIO)

Market Cap	29.06B -15.7%
Revenue (ttm)	8.97B +10.8%
Net Income	500.38M -39.0%
EPS	4.99 -39.0%
Shares Out	n/a
PE Ratio	58.07
Forward PE	n/a
Dividend	0.10 (0.04%)
Ex-Dividend Date	Sep 22, 2025

Volume	15,736
Average Volume	59,140
Open	283.30
Previous Close	288.70
Day's Range	279.30 - 290.70
52-Week Range	268.00 - 407.85
Beta	-0.14
RSI	49.89
Earnings Date	May 29, 2026

About Gufic Biosciences

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (P...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 1,484
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GUFICBIO

Financial Performance

In fiscal year 2025, Gufic Biosciences's revenue was 8.20 billion, an increase of 1.63% compared to the previous year's 8.07 billion. Earnings were 696.50 million, a decrease of -19.14%.